Patient description: The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Helicobacter Pylori Infection Major 1. Subject must be 18 to 45 years of age (inclusive). 2. Subject must have 2 positive Urea Breath Tests (UBT) obtaining during screening, and no other clinically significant disease (i.e., hematology, clinical chemistries and urinalysis tests must be within study-defined ranges (See Appendix B). Clinical tests must be performed within 14 days of receiving first dose of study drug. 3. Body Mass Index (BMI) must be between 18 and 30 kg/m2 inclusive. 4. Subject must be able to give voluntary written informed consent before any study related procedure is performed. 5. If female, has no childbearing potential or agrees to avoid becoming pregnant from the day of screening through their entire participation in the trial (Day 42) by using one of the following acceptable methods of birth control plus recommended use of a barrier method (condom) by the male partner (even if vasectomized): 1. intrauterine contraceptive device; or 2. diaphragm in combination with contraceptive jelly, cream, or foam; or 3. spermicide; or 4. abstinence. Major  A history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which would jeopardize the safety of the subject or impact the validity of the study results. 2. Abnormal diet during the 4 weeks preceding the study. 3. Use of any OTC or prescription medication, including vitamins and herbal supplements, within 7 days prior to Day 1 of the study, unless the substance would not likely impact on the conduct of this study. 4. Current medical condition (other than H. pylori infection) requiring treatment with medication, either prescription or OTC. 5. Treatment with any known CYP450 enzyme altering drugs such as azoles, antifungals, barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to Day 1 of the study. 6. Positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody and/or a positive urine screen for alcohol or drugs of abuse. 7. Baseline QTc interval >450 msec (males) or >470 msec (females)or a family history of prolonged QTc syndrome or premature cardiac death